Trial Profile
A protocol for the safety and tolerance of intravenous isophosphoramide mustard (IPM) in patients with advanced cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Palifosfamide (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 22 Sep 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2008 The expected completion date for this trial is now 1 Feb 2008 as reported by ClinicalTrials.gov.